Drug Profile
Transient receptor potential channel inhibitor - Boehringer Ingelheim/Hydra Biosciences
Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Hydra Biosciences
- Class Neuroprotectants; Small molecules; Urologics
- Mechanism of Action TRPC4 cation channel inhibitors; TRPC5 cation channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I CNS disorders; Kidney disorders
Most Recent Events
- 07 Dec 2022 Transient receptor potential channel inhibitor is still in phase I trials for Kidney disorders in USA and Germany (Boehringer Ingelheim pipeline, December 2022)
- 30 Sep 2020 Phase-I clinical trials in CNS disorders in Germany (unspecified route) (Boehringer Ingelheim pipeline, September 2020)
- 30 Sep 2020 Phase-I clinical trials in CNS disorders in USA (unspecified route) (Boehringer Ingelheim pipeline, September 2020)